Evidence map›Paper›PMID 34782457›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Lipofuscin causes atypical necroptosis through lysosomal membrane permeabilization.

Chendong Pan, Kalpita Banerjee, Guillermo L Lehmann, Dena Almeida, Katherine A Hajjar, Ignacio Benedicto, Zhichun Jiang, Roxana A Radu, David H Thompson, Enrique Rodriguez-Boulan and 1 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Lysosomal homeostasis at the crossroads of neurodegeneration.The Journal of clinical investigation · 2026
    Review
  15. iScience · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Chendong PanDepartment of Ophthalmology, Weill Cornell Medicine, Margaret Dyson Vision Research Institute, New York, NY 10065.ORCID 0000-0003-3058-7247
Kalpita BanerjeeDepartment of Ophthalmology, Weill Cornell Medicine, Margaret Dyson Vision Research Institute, New York, NY 10065.ORCID 0000-0001-5316-439X
Guillermo L LehmannDepartment of Ophthalmology, Weill Cornell Medicine, Margaret Dyson Vision Research Institute, New York, NY 10065.
Dena AlmeidaDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10065.ORCID 0000-0002-7286-2027
Katherine A HajjarDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10065.ORCID 0000-0003-3977-4356
Ignacio BenedictoDepartment of Ophthalmology, Weill Cornell Medicine, Margaret Dyson Vision Research Institute, New York, NY 10065.
Zhichun JiangUCLA Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, CA 90095.
Roxana A RaduUCLA Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, CA 90095.ORCID 0000-0002-5064-6403
David H ThompsonDepartment of Chemistry, Purdue University, West Lafayette, IN 28029.ORCID 0000-0002-0746-1526
Enrique Rodriguez-BoulanDepartment of Ophthalmology, Weill Cornell Medicine, Margaret Dyson Vision Research Institute, New York, NY 10065.
Marcelo M NociariDepartment of Ophthalmology, Weill Cornell Medicine, Margaret Dyson Vision Research Institute, New York, NY 10065; mnociari@med.cornell.edu.
Cornell University · USUniversity of California, Los Angeles · USPurdue University West Lafayette · US

Funding

RETINA--REVERSED POLARITY IN RPER01EY008538 · NEI · WEILL MEDICAL COLL OF CORNELL UNIV · PI RODRIGUEZ-BOULAN, ENRIQUE J · 1991 to 2020
$13.4M
SORTING OF PLASMA MEMBRANE PROTEINS IN EPITHELIAL CELLSR01GM034107 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI RODRIGUEZ-BOULAN, ENRIQUE J · 1985 to 2019
$9.6M
Modulation of Lipid Bisretinoids Clearance with Beta-CyclodextrinsR01EY027422 · NEI · WEILL MEDICAL COLL OF CORNELL UNIV · PI NOCIARI, MARCELO M · 2017 to 2021
$2.4M
NEI NIH HHS R01 EY008538NEI NIH HHS R01 EY027422NIGMS NIH HHS R01 GM034107
6 · The paper itself

Abstract

Lipofuscin granules enclose mixtures of cross-linked proteins and lipids in proportions that depend on the tissue analyzed. Retinal lipofuscin is unique in that it contains mostly lipids with very little proteins. However, retinal lipofuscin also presents biological and physicochemical characteristics indistinguishable from conventional granules, including indigestibility, tendency to cause lysosome swelling that results in rupture or defective functions, and ability to trigger NLRP3 inflammation, a symptom of low-level disruption of lysosomes. In addition, like conventional lipofuscins, it appears as an autofluorescent pigment, considered toxic waste, and a biomarker of aging. Ocular lipofuscin accumulates in the retinal pigment epithelium (RPE), whereby it interferes with the support of the neuroretina. RPE cell death is the primary cause of blindness in the most prevalent incurable genetic and age-related human disorders, Stargardt disease and age-related macular degeneration (AMD), respectively. Although retinal lipofuscin is directly linked to the cell death of the RPE in Stargardt, the extent to which it contributes to AMD is a matter of debate. Nonetheless, the number of AMD clinical trials that target lipofuscin formation speaks for the potential relevance for AMD as well. Here, we show that retinal lipofuscin triggers an atypical necroptotic cascade, amenable to pharmacological intervention. This pathway is distinct from canonic necroptosis and is instead dependent on the destabilization of lysosomes. We also provide evidence that necroptosis is activated in aged human retinas with AMD. Overall, this cytotoxicity mechanism may offer therapeutic targets and markers for genetic and age-related diseases associated with lipofuscin buildups.

Indexed as

AgingAlcohol OxidoreductasesAnimalsATP-Binding Cassette TransportersCell DeathHumansIntracellular MembranesLipofuscinLysosomesMacular DegenerationMiceMice, Inbred C57BLNecroptosisNLR Family, Pyrin Domain-Containing 3 ProteinRetinaRetinal Pigment EpitheliumAbca4 protein, mouseAlcohol OxidoreductasesATP-Binding Cassette TransportersHSD17B6 protein, mouseLipofuscinNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanaginglipid-bisretinoidsLipofuscinLMPnecroptosis

Identifiers

PMID34782457
PMCPMC8617501
OpenAlexW3214104719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.